Guiding the global evolution of cytogenetic testing for hematologic malignancies

Autores
Akkari, Yassmine M.N.; Baughn, Linda B.; Dubuc, Adrian M.; Smith, Adam C.; Mallo, Mar; Dal Cin, Paola; Diez Campelo, Maria; Gallego, Marta S.; Granada Font, Isabel; Haase, Detlef T.; Schlegelberger, Brigitte; Slavutsky, Irma Rosa; Mecucci, Cristina; Levine, Ross L.; Hasserjian, Robert P.; Solé, Francesc; Levy, Brynn; Xu, Xinjie
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.
Fil: Akkari, Yassmine M.N.. Legacy Health; Estados Unidos
Fil: Baughn, Linda B.. Mayo Clinic Cancer Center; Estados Unidos
Fil: Dubuc, Adrian M.. Harvard Medical School; Estados Unidos
Fil: Smith, Adam C.. University of Toronto; Canadá
Fil: Mallo, Mar. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Dal Cin, Paola. Harvard Medical School; Estados Unidos
Fil: Diez Campelo, Maria. Universidad de Salamanca; España
Fil: Gallego, Marta S.. Hospital Italiano; Argentina
Fil: Granada Font, Isabel. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Haase, Detlef T.. Universität Göttingen; Alemania
Fil: Schlegelberger, Brigitte. Leibniz Universitat Hannover; Alemania
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Mecucci, Cristina. Università di Perugia; Italia
Fil: Levine, Ross L.. Memorial Sloan-kettering Cancer Center; Estados Unidos
Fil: Hasserjian, Robert P.. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;
Fil: Solé, Francesc. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Levy, Brynn. Columbia University; Estados Unidos
Fil: Xu, Xinjie. Mayo Clinic Cancer Center; Estados Unidos
Materia
CYTOGENETICS
G-BANDING
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/215947
Acceder
id CONICETDig_68917eda00b313811cb965698621ecb3
oai_identifier_str oai:ri.conicet.gov.ar:11336/215947
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Guiding the global evolution of cytogenetic testing for hematologic malignanciesAkkari, Yassmine M.N.Baughn, Linda B.Dubuc, Adrian M.Smith, Adam C.Mallo, MarDal Cin, PaolaDiez Campelo, MariaGallego, Marta S.Granada Font, IsabelHaase, Detlef T.Schlegelberger, BrigitteSlavutsky, Irma RosaMecucci, CristinaLevine, Ross L.Hasserjian, Robert P.Solé, FrancescLevy, BrynnXu, XinjieCYTOGENETICSG-BANDINGhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.Fil: Akkari, Yassmine M.N.. Legacy Health; Estados UnidosFil: Baughn, Linda B.. Mayo Clinic Cancer Center; Estados UnidosFil: Dubuc, Adrian M.. Harvard Medical School; Estados UnidosFil: Smith, Adam C.. University of Toronto; CanadáFil: Mallo, Mar. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Dal Cin, Paola. Harvard Medical School; Estados UnidosFil: Diez Campelo, Maria. Universidad de Salamanca; EspañaFil: Gallego, Marta S.. Hospital Italiano; ArgentinaFil: Granada Font, Isabel. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Haase, Detlef T.. Universität Göttingen; AlemaniaFil: Schlegelberger, Brigitte. Leibniz Universitat Hannover; AlemaniaFil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Mecucci, Cristina. Università di Perugia; ItaliaFil: Levine, Ross L.. Memorial Sloan-kettering Cancer Center; Estados UnidosFil: Hasserjian, Robert P.. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;Fil: Solé, Francesc. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);Fil: Levy, Brynn. Columbia University; Estados UnidosFil: Xu, Xinjie. Mayo Clinic Cancer Center; Estados UnidosAmerican Society of Hematology2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/215947Akkari, Yassmine M.N.; Baughn, Linda B.; Dubuc, Adrian M.; Smith, Adam C.; Mallo, Mar; et al.; Guiding the global evolution of cytogenetic testing for hematologic malignancies; American Society of Hematology; Blood; 139; 15; 4-2022; 2273-22840006-49711528-0020CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://ashpublications.org/blood/article/139/15/2273/484041/Guiding-the-global-evolution-of-cytogeneticinfo:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2021014309info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:21:05Zoai:ri.conicet.gov.ar:11336/215947instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:21:05.905CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Guiding the global evolution of cytogenetic testing for hematologic malignancies
title Guiding the global evolution of cytogenetic testing for hematologic malignancies
spellingShingle Guiding the global evolution of cytogenetic testing for hematologic malignancies
Akkari, Yassmine M.N.
CYTOGENETICS
G-BANDING
title_short Guiding the global evolution of cytogenetic testing for hematologic malignancies
title_full Guiding the global evolution of cytogenetic testing for hematologic malignancies
title_fullStr Guiding the global evolution of cytogenetic testing for hematologic malignancies
title_full_unstemmed Guiding the global evolution of cytogenetic testing for hematologic malignancies
title_sort Guiding the global evolution of cytogenetic testing for hematologic malignancies
dc.creator.none.fl_str_mv Akkari, Yassmine M.N.
Baughn, Linda B.
Dubuc, Adrian M.
Smith, Adam C.
Mallo, Mar
Dal Cin, Paola
Diez Campelo, Maria
Gallego, Marta S.
Granada Font, Isabel
Haase, Detlef T.
Schlegelberger, Brigitte
Slavutsky, Irma Rosa
Mecucci, Cristina
Levine, Ross L.
Hasserjian, Robert P.
Solé, Francesc
Levy, Brynn
Xu, Xinjie
author Akkari, Yassmine M.N.
author_facet Akkari, Yassmine M.N.
Baughn, Linda B.
Dubuc, Adrian M.
Smith, Adam C.
Mallo, Mar
Dal Cin, Paola
Diez Campelo, Maria
Gallego, Marta S.
Granada Font, Isabel
Haase, Detlef T.
Schlegelberger, Brigitte
Slavutsky, Irma Rosa
Mecucci, Cristina
Levine, Ross L.
Hasserjian, Robert P.
Solé, Francesc
Levy, Brynn
Xu, Xinjie
author_role author
author2 Baughn, Linda B.
Dubuc, Adrian M.
Smith, Adam C.
Mallo, Mar
Dal Cin, Paola
Diez Campelo, Maria
Gallego, Marta S.
Granada Font, Isabel
Haase, Detlef T.
Schlegelberger, Brigitte
Slavutsky, Irma Rosa
Mecucci, Cristina
Levine, Ross L.
Hasserjian, Robert P.
Solé, Francesc
Levy, Brynn
Xu, Xinjie
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CYTOGENETICS
G-BANDING
topic CYTOGENETICS
G-BANDING
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.
Fil: Akkari, Yassmine M.N.. Legacy Health; Estados Unidos
Fil: Baughn, Linda B.. Mayo Clinic Cancer Center; Estados Unidos
Fil: Dubuc, Adrian M.. Harvard Medical School; Estados Unidos
Fil: Smith, Adam C.. University of Toronto; Canadá
Fil: Mallo, Mar. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Dal Cin, Paola. Harvard Medical School; Estados Unidos
Fil: Diez Campelo, Maria. Universidad de Salamanca; España
Fil: Gallego, Marta S.. Hospital Italiano; Argentina
Fil: Granada Font, Isabel. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Haase, Detlef T.. Universität Göttingen; Alemania
Fil: Schlegelberger, Brigitte. Leibniz Universitat Hannover; Alemania
Fil: Slavutsky, Irma Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Mecucci, Cristina. Università di Perugia; Italia
Fil: Levine, Ross L.. Memorial Sloan-kettering Cancer Center; Estados Unidos
Fil: Hasserjian, Robert P.. Massachusetts General Hospital ; Department Of Medicine ; Harvard Medical School;
Fil: Solé, Francesc. Institut D`investigació Biomedica de Girona Dr. Josep Trueta (idib`gi);
Fil: Levy, Brynn. Columbia University; Estados Unidos
Fil: Xu, Xinjie. Mayo Clinic Cancer Center; Estados Unidos
description Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists, and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, logistic, technical, and financial implications, we provide points to consider for the global evolution of cytogenetic testing.
publishDate 2022
dc.date.none.fl_str_mv 2022-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/215947
Akkari, Yassmine M.N.; Baughn, Linda B.; Dubuc, Adrian M.; Smith, Adam C.; Mallo, Mar; et al.; Guiding the global evolution of cytogenetic testing for hematologic malignancies; American Society of Hematology; Blood; 139; 15; 4-2022; 2273-2284
0006-4971
1528-0020
CONICET Digital
CONICET
url http://hdl.handle.net/11336/215947
identifier_str_mv Akkari, Yassmine M.N.; Baughn, Linda B.; Dubuc, Adrian M.; Smith, Adam C.; Mallo, Mar; et al.; Guiding the global evolution of cytogenetic testing for hematologic malignancies; American Society of Hematology; Blood; 139; 15; 4-2022; 2273-2284
0006-4971
1528-0020
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://ashpublications.org/blood/article/139/15/2273/484041/Guiding-the-global-evolution-of-cytogenetic
info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.2021014309
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society of Hematology
publisher.none.fl_str_mv American Society of Hematology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082595447635968
score 13.22299

Publicaciones similares